Answer
Women of childbearing potential should use effective contraception during risankizumab treatment and for at least 21 weeks after stopping treatment.
Sources for this answer
- Skyrizi 150 mg solution for injection in pre-filled penAbbVie Ltd · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 11Document updated
Sources checked